Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of CDP-Choline (Citicoline) and Oxiracetam — mechanism, side effects, legal status, and pricing.
CDP-choline (citicoline) is a non-peptide cytidine nucleotide-choline conjugate that serves as an intermediate in phosphatidylcholine biosynthesis. It is approved as a prescription drug for stroke and cognitive disorders in Japan and parts of Europe but sold only as a dietary supplement ingredient in the United States, where it is not FDA-approved as a drug. Human evidence is mixed and indication-dependent: small trials report modest memory improvements in healthy/older adults, but the largest phase 3 RCT (COBRIT, n=1,213 traumatic brain injury patients) found no benefit over placebo.
Oxiracetam is a non-peptide racetam-class cognitive enhancer, structurally the 4-hydroxy analog of piracetam. It is approved as a prescription drug for dementia in Italy (since 1984) and China, but is NOT FDA-approved in the United States. The FDA has classified oxiracetam as a 'new drug' requiring approval and determined it does not qualify as a dietary supplement; in the US it is sold only as an unregulated gray-market research chemical.
CDP-Choline (Citicoline)
Oxiracetam
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
CDP-Choline (Citicoline)
No pricing data yet.
Check CDP-Choline (Citicoline) prices →Oxiracetam
No pricing data yet.
Check Oxiracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
CDP-Choline (Citicoline)
No COA data yet.
Submit testing data →Oxiracetam
2
COAs
99.4%
Avg purity
2
Labs
Human evidence is mixed and indication-dependent. Small-to-moderate placebo-controlled RCTs in healthy/older adults and age-associated memory impairment report modest verbal/episodic memory improvements at ~500–1,000 mg/day over weeks to months. However, the largest trial to date—COBRIT, a phase 3 double-blind placebo-controlled RCT in 1,213 traumatic brain injury patients—found no benefit over placebo on functional or cognitive outcomes (GOS-E favorable outcome 35.4% citicoline vs 35.6% placebo; global OR 0.98, 95% CI 0.83–1.15). Evidence for Alzheimer's disease and MCI is described in reviews as insufficient and inconsistent. In preclinical models, aged rats with hippocampal damage showed reduced long-term memory impairment with dietary CDP-choline supplementation, and mice subjected to ischemic stroke showed SIRT1-dependent reduction in cerebral infarct volume.
Key references
Multiple placebo-controlled human trials exist in dementia, organic brain syndrome, and traumatic brain injury populations, plus human pharmacokinetic studies. One double-blind controlled trial in elderly organic-brain-syndrome patients used doses titrated from 400–2400 mg/day; a separate placebo-controlled trial in senile dementia of Alzheimer type and multi-infarct dementia used 800 mg twice daily and reported improvement on cognitive measures versus placebo. Preclinical findings include AMPA receptor modulation and enhanced neurotransmitter release in rat hippocampal preparations, and identification of the (S)-enantiomer as the active component alleviating cognitive impairment in a rat chronic cerebral hypoperfusion model. Oral bioavailability in humans is ~56% (versus 28–42% in rats, 81–90% in dogs), with predominantly renal excretion of unchanged drug.
CDP-Choline (Citicoline) and Oxiracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs